Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company pioneering novel cancer therapies
and dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against
nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm's Selective
Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein
XPO1. The company was founded in 2008 with a vision of pioneering a potentially new approach to treating
patients with certain blood cancers. US-NON-08/18-00002 (1/2021)

For more information visit our Company Website  and  Product Website

Back to Exhibit Hall    

Meet with Gregg

Gregg Stewart 
Hematology/Oncology Specialist - Pittsburgh, PA
724-316-4448 | Gregg.Stewart@karyopharm.com

Information to join Zoom:

Meeting URL
Meeting ID: 
926 4481 3946
Passcode: 085776

Phone:  US: +13126266799,,92644813946#,,,,*085776# or

















Learn more about XPOVIO Indications

Learn more about our MOA

Prescribing Information

Patient Resources

Social Media Links:

Twitter  LinkedIn  You Tube  Facebook